French AFU Cancer Committee Guideline – Update 2026–2028: Adrenal incidentalomas and adrenal cancers - 20/11/26
, Thibaut Murez a, c, Annabelle Goujon a, d, Rossella Libé e, Laurence Rocher a, f, g, Agate Escoffier a, h, Nicolas Branger a, i, Aude Fléchon a, j, Philippe Camparo a, k, Stephan Levy a, l, Paul Neuville a, m, Morgan Roupret a, nAbstract |
Introduction |
Although the majority of adrenal masses are benign and nonfunctional, it is important to investigate them because of their serious endocrine potential and because of the presence of certain cancers. Malignant adrenal tumors (MATs) mainly include adrenocortical carcinomas (ACCs), malignant pheochromocytomas (MPCs), and adrenal metastases (AMs). This article updates guidelines for the management of adrenal incidentalomas (AIs) and, where appropriate, the oncological management of MATs.
Materials and methods |
The multidisciplinary working group updated the CCAFU 2024 guidelines for the management of benign or malignant adrenal incidentalomas on the basis of a comprehensive Pubmed review in 2026.
Results |
The work-up for the malignancy of an adrenal incidentaloma includes a full history, physical examination, and a biochemical/hormonal assessment to look for subclinical hormone secretion. Diagnostic hypotheses are sometimes available at this stage, but morphological and functional imaging and histological analysis enable the malignancy assessment to be completed and a carcinological diagnosis to be made. Subsequent management decisions, such as the frequency and modality of surveillance or the surgical approach, depend on the findings of this initial assessment. ACC and MPC are mostly sporadic in origin, but a hereditary origin is possible. ACC can be suspected preoperatively, but only a histological examination enables a definitive diagnosis. The diagnosis of PCM is more complex and is based on clinical, biological, and imaging findings. A definitive diagnosis of MS requires a percutaneous biopsy.
Conclusions |
AIs are common but rarely malignant. The highly specific management of malignant adrenal tumors justifies their referral to the COMETE network in France. A management error is a significant factor in life-threatening situations. Therefore, all patients with MATs should be referred to an expert center.
Le texte complet de cet article est disponible en PDF.Keywords : Adrenal incidentaloma, Adrenocortical carcinoma, Malignant pheochromocytoma, Adrenal metastasis
Plan
| ☆ | This article provides urologists with recommendations for an initial diagnostic work-up and the subsequent management (discontinuation of follow-up, monitoring or surgery and/or systemic treatment) of unilateral adrenal incidentaloma. This 2026 update clarifies the role of expert centers, simplifies the diagnostic strategy for adrenal incidentalomas, and updates the indications for oncological surgery in light of the latest international recommendations and the scientific literature available on PubMed in 2026.. |
Vol 36 - N° 11
Article 103227- janvier 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
